mRNA Therapeutics CDMO Global Market Opportunities and Strategies to 2035

This report describes and explains the mRNA therapeutics CDMO market and covers 2020-2025, termed the historic period, and 2025-2030, 2035F termed the forecast period. The report evaluates the market across each region and for the major economies within each region.

The global mRNA therapeutics CDMO market reached a value of nearly $4.74 billion in 2025, having grown at a compound annual growth rate (CAGR) of 14% since 2020. The market is expected to grow from $4.74 billion in 2025 to $8.13 billion in 2030 at a rate of 11.4%. The market is then expected to grow at a CAGR of 10.3% from 2030 and reach $13.26 billion in 2035.

Growth in the historic period resulted from increasing demand for personalized and next-generation vaccines, government funding for domestic vaccine and RNA manufacturing capacity, increasing cancer incidence and expansion of clinical trials and robust therapeutic pipeline. Factors that negatively affected growth in the historic period were high manufacturing costs and limited specialized manufacturing capacity.

Going forward, growth in multi-valent and combination mRNA vaccines, increasing outsourcing of late-stage and commercial manufacturing, venture capital and pharma investment in RNA and growing trend of pharma-CDMO partnerships will drive the growth. Factors that could hinder the growth of the mRNA therapeutics CDMO market in the future include instability and degradation of RNA targets and complexity of RNA-based drug discovery and trade war and tariff.

Market trends for the mRNA therapeutics CDMO market include integrated sequence optimization and GMP manufacturing partnership accelerates mRNA program development, advancement of next-generation lipid nanoparticle delivery platforms, strategic platform-manufacturing collaboration accelerates scalable mRNA development, rapid personalized mRNA manufacturing enables breakthrough gene-editing therapies and large-scale manufacturing expansion strengthens regional mRNA supply and readiness.

The mRNA therapeutics CDMO market is segmented by type of service into development services, manufacturing services and laboratory services. The manufacturing services market was the largest segment of the mRNA therapeutics CDMO market segmented by type of service, accounting for 47.5% or $2.25 billion of the total in 2025. Going forward, the manufacturing services segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by type of service, at a CAGR of 13.5% during 2025-2030.

The mRNA therapeutics CDMO market is segmented by indication into infectious diseases, metabolic and genetic diseases, cardiovascular and cerebrovascular diseases, oncology and other indications. The infectious diseases was the largest segment of the mRNA therapeutics CDMO market segmented by indication, accounting for 38% or $1.8 billion of the total in 2025. Going forward, the oncology segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by indication, at a CAGR of 12.4% during 2025-2030.

The mRNA therapeutics CDMO market is segmented by application into viral vaccines, protein replacement therapies and cancer immunotherapies. The viral vaccines market was the largest segment of the mRNA therapeutics CDMO market segmented by application, accounting for 40.1% or $1.9 billion of the total in 2025. Going forward, the cancer immunotherapies segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by application, at a CAGR of 12.9% during 2025-2030.

The mRNA therapeutics CDMO market is segmented by end user into pharmaceutical companies, biotechnology companies, academic institutions and research organizations. The biotechnology companies market was the largest segment of the mRNA therapeutics CDMO market segmented by end user, accounting for 64.7% or $3.06 billion of the total in 2025. Going forward, the biotechnology companies segment is expected to be the fastest-growing segment in the mRNA therapeutics CDMO market segmented by end user, at a CAGR of 12.9% during 2025-2030.

North America was the largest region in the mRNA therapeutics CDMO market, accounting for 38% or $1.8 billion of the total in 2025. It was followed by Asia Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the mRNA therapeutics CDMO market will be Asia Pacific and South America where growth will be at CAGRs of 14.3% and 11.6% respectively. These will be followed by Eastern Europe and Africa where the markets are expected to grow at CAGRs of 11.4% and 9.1% respectively.

The global mRNA therapeutics CDMO market is fairly concentrated, with large players operating in the market. The top 10 competitors in the market made up 36.7% of the total market in 2024. Lonza Group was the largest competitor with a 5.6% share of the market, followed by Thermo Fisher Scientific Inc. (Patheon) with 5.5%, Samsung Biologics Co. Ltd. with 4.7%, Wuxi Biologics (WuXi Vaccines), with 4.5%, Catalent, Inc. (Catalent Biologics Inc.), with 4.1%, Danaher Corp.(Aldevron) with 3.5%, Merck KGaA (Merck Millipore) with 3.4%, AGC Biologics GmbH with 2%, Genscript Biotech Corp. (ProBio)with 1.8% and FUJIFILM Holdings Corporation (Fujifilm Pharmaceuticals U.S.A., Inc) with 1.6%.

The top opportunities in the mRNA therapeutics CDMO market segmented by type of service will arise in the manufacturing services segment, which will gain $2.0 billion of global annual sales by 2030. The top opportunities in the mRNA therapeutics CDMO market segmented by indication will arise in the infectious diseases segment, which will gain $1.3 billion of global annual sales by 2030. The top opportunities in the mRNA therapeutics CDMO market segmented by application will arise in the cancer immunotherapies segment, which will gain $1.41 billion of global annual sales by 2030. The top opportunities in the mRNA therapeutics CDMO market segmented by end user will arise in the biotechnology companies segment, which will gain $2.56 billion of global annual sales by 2030. The mRNA therapeutics CDMO market size will gain the most in the USA at $1.03 billion.

Player-adopted strategies in the mRNA therapeutics CDMO market include focuses ON business operations through new product developments, business expertise and business offerings.

Market-trend-based strategies for the mRNA therapeutics CDMO market include focus on strategic partnerships to integrate advanced mRNA sequence optimization with end-to-end GMP manufacturing, collaborative development of advanced lipid nanoparticle delivery platforms to enhance stability, targeted delivery, adopting strategic collaborations to integrate proprietary mRNA platform technologies, personalized mRNA manufacturing integrated with gene-editing technologies and expanding large-scale manufacturing infrastructure in strategic regions to support end-to-end mRNA production.

To take advantage of the opportunities, the analyst recommends the mRNA therapeutics CDMO to focus on integrated partnerships for end-to-end mrna development, focus on collaborative lnp platform development for scalable mrna delivery, focus on rapid personalized mrna manufacturing integration, focus on expanding regional manufacturing capacity and integrated mrna capabilities, focus on high-growth manufacturing services and core technology bottlenecks, expand in emerging markets, continue to focus on developed markets, focus on expanding global cdmo distribution networks through strategic partnerships, focus on value-based tiered pricing with cost transparency, focus on scientific credibility and clinical evidence communication, focus on targeted engagement and strategic partnerships, focus on building specialized talent and partnership capabilities for biotechnology clients.

This product will be delivered within 3-5 business days.